BTWM
ACRS icon

Baker Tilly Wealth Management’s Aclaris Therapeutics ACRS Stock Holding History

Baker Tilly Wealth Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,773
Closed -$212K – 527
2021
Q3 		$212K Buy
11,773
+34
+0.3% +$545 0.03% 482
2021
Q2 		$206K Hold
11,739
– – 0.03% 477
2021
Q1 		$296K Buy
+11,739
New +$230K 0.06% 360

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baker Tilly Wealth Management's ACRS Position: Q4 2021 in Review

Baker Tilly Wealth Management sold out of Aclaris Therapeutics (ACRS) in Q4 2021, closing a stake of 11,773 shares — an estimated $212K sold.

Baker Tilly Wealth Management first reported a position in ACRS in Q1 2021 and held it in 3 quarters. The position peaked at $296K in Q1 2021. 133 funds tracked by Wall St. Rank hold ACRS as of Q4 2021.

  • Baker Tilly Wealth Management reported no remaining Aclaris Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Baker Tilly Wealth Management sold 11,773 Aclaris Therapeutics shares in Q4 2021, an estimated $212K.
  • Baker Tilly Wealth Management first reported a position in Aclaris Therapeutics in Q1 2021 and held it in 3 quarters.
  • Baker Tilly Wealth Management's Aclaris Therapeutics position peaked at $296K in Q1 2021.
  • 133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2021.

Based on Baker Tilly Wealth Management's 13F filing for Q4 2021, filed 8 Feb 2022.